Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?

Vaccination Strategies Based on NK Cell and ILC Memory

Megan A. Cooper,^{1,2} Todd A. Fehniger,³ and Marco Colonna²

¹Department of Pediatrics, Division of Rheumatology, Washington University School of Medicine, St. Louis, Missouri 63110

²Department of Pathology and Immunology, Washington University School of Medicine, St. Louis, Missouri 63110

³Division of Oncology, Department of Medicine, Washington University School of Medicine, St. Louis, Missouri 63110

Correspondence: cooper_m@kids.wustl.edu; mcolonna@pathology.wustl.edu

Studies over the last decade have decisively shown that innate immune natural killer (NK) cells exhibit enhanced long-lasting functional responses following a single activation event. With the increased recognition of memory and memory-like properties of NK cells, questions have arisen with regard to their ability to effectively mediate vaccination responses in humans. Moreover, recently discovered innate lymphoid cells (ILCs) could also potentially exhibit memory-like functions. Here, we review different forms of NK cell memory, and speculate about the ability of these cells and ILCs to meaningfully contribute to vaccination responses.

GREAT DEBATES

What are the most interesting topics likely to come up over dinner or drinks with your colleagues? Or, more importantly, what are the topics that *don't* come up because they are a little too controversial? In ***Immune Memory and Vaccines: Great Debates***, Editors Rafi Ahmed and Shane Crotty have put together a collection of articles on such questions, written by thought leaders in these fields, with the freedom to talk about the issues as they see fit. This short, innovative format aims to bring a fresh perspective by encouraging authors to be opinionated, focus on what is most interesting and current, and avoid restating introductory material covered in many other reviews.

The Editors posed 13 interesting questions critical for our understanding of vaccines and immune memory to a broad group of experts in the field. In each case, several different perspectives are provided. Note that while each author knew that there were additional scientists addressing the same question, they did not know who these authors were, which ensured the independence of the opinions and perspectives expressed in each article. Our hope is that readers enjoy these articles and that they trigger many more conversations on these important topics.

Editors: Shane Crotty and Rafi Ahmed

Additional Perspectives on Immune Memory and Vaccines: Great Debates available at www.cshperspectives.org

Copyright © 2018 Cold Spring Harbor Laboratory Press; all rights reserved; doi: 10.1101/cshperspect.a029512

Cite this article as *Cold Spring Harb Perspect Biol* 2018;10:a029512

M.A. Cooper et al.

Natural killer (NK) cells and innate lymphoid cells (ILCs) derive from the common lymphoid progenitor (CLP) and depend on the interleukin 2 receptor common γ chain (IL-2rg, γ_c) for development (Diefenbach et al. 2014; Eberl et al. 2015). These cells are distinct from T and B lymphocytes for their lack of recombined antigen-specific receptors (Fig. 1). Although seemingly limited in their ability to recognize antigens, a fundamental attribute of T- and B-cell immunologic memory, during the past decade it has become clear that NK cells also possess features of memory, and have the capacity to learn from prior experiences. Whether ILCs have attributes of memory is not known. In the following paragraphs, we will discuss different forms of NK cell memory, speculate about the ability of ILCs to learn from experience, and propose potentially relevant vaccination strategies based on NK and ILC memory.

DIFFERENT FORMS OF NK CELL MEMORY

NK cells have classically been characterized as innate immune lymphocytes capable of killing target cells without prior sensitization or major histocompatibility complex (MHC) restriction (Yokoyama 2013). NK cells express a genetically determined repertoire of germline-encoded activating and inhibitory receptors that control NK cell education and target cell recognition and activation/killing. Despite their lack of antigen-specific receptors, over the past decade it has become clear that NK cells also possess features of memory and have the capacity to learn from prior experiences. Three primary routes of memory NK cell differentiation have been described thus far: antigen-specific liver-resident NK cell memory, cytomegalovirus (CMV)-driven memory, and cytokine-induced memory.

The first evidence of NK cell memory came from the von Andrian Laboratory with the finding that a subset of NK cells can mediate hapten-specific contact hypersensitivity (CHS) (O'Leary et al. 2006; Paust et al. 2010). Hapten-specific NK cell memory is limited to a specific subset of liver-resident cells in the mouse with the phenotype $\text{NK1.1}^+\text{DX5}^-\text{CXCR6}^+\text{CD49a}^+$ (O'Leary et al. 2006; Paust et al. 2010; Peng

et al. 2013). Liver-resident NK cells show specific memory against a variety of haptens and other antigens, including virus-like particles (VLPs), through an unidentified recognition mechanism (Paust et al. 2010). In addition to antigen, cytokine signals, including IL-12, interferon (IFN)- γ , IFN- α , and IL-18 are required for development of memory (Majewska-Szczepanik et al. 2013; van den Boorn et al. 2016). It is unknown whether a similar subset of liver-resident memory cells exists in humans, but a study in rhesus macaques suggest antigen-specific NK cells may also exist in primates (Reeves et al. 2015).

NK cells also have the capacity to alter their function following infection with CMV. Half of the NK cells in C57BL/6 mice express the activating receptor Ly49H, which specifically recognizes the murine CMV (MCMV) ligand m157, likely as the result of positive selection of this receptor recognizing a nearly-ubiquitous pathogen (O'Sullivan et al. 2015). During MCMV infection, Ly49H^+ NK cells specifically proliferate and are required for survival (Dokun et al. 2001). The Lanier Laboratory first showed that Ly49H^+ cells have enhanced functionality following MCMV infection, can be detected months after infection, and provide superior protection in a neonatal infection model compared with naïve Ly49H^+ NK cells (Sun et al. 2009). MCMV-induced memory NK cells appear specific, and do not have enhanced functionality against influenza or *Listeria* infection (Min-Oo and Lanier 2014).

Human CMV (HCMV) infection is associated with the expansion of unique subsets of human NK cells, primarily marked by a mature phenotype ($\text{CD56}^{\text{dim}}\text{CD57}^+\text{NKG2A}^+$) and high expression of the activating receptor CD95/NKG2C , which recognizes the nonclassical MHC molecule HLA-E (Guma et al. 2004; Foley et al. 2012; Rolle and Brodin 2016). The emergence and long-term maintenance of $\text{NKG2C}^{\text{high}}$ NK cells in individuals with a history of CMV, and their expansion during acute infection with HCMV and other viruses (in HCMV-experienced individuals) has led to their description as HCMV-adaptive or "memory-like" cells (Holmes and Bryceson 2016; Rolle and Brodin 2016). Although most HCMV-adaptive NK cells

Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?

Figure 1. Pathways for generation of memory natural killer (NK) cells and possibly memory innate lymphoid cells (ILCs). Naïve NK cells can differentiate and expand into memory NK cells with increased life span and effector functions through three primary routes: antigen-specific stimulation through yet-undefined receptors; cytomegalovirus (CMV)-driven stimulation through Ly-49H in mouse and, possibly, NKG2C in human; and cytokine-induced stimulation. Memory ILCs have not been reported. However, because they lack antigen-specific receptors and do not express receptors analogous to the CMV receptors of NK cells, they may acquire memory-like functions only through stimulation of cytokine receptors.

express high levels of NKG2C, this activating receptor is not known to specifically recognize an HCMV antigen, and HCMV-adaptive NK cells were also recently identified in individuals genetically deficient in NKG2C (Liu et al. 2016; Wagner and Fehniger 2016). Recently, human NK cells lacking the intracellular signaling adapter Fc ϵ R γ were identified as HCMV-adaptive NK cells (Hwang et al. 2012; Zhang et al. 2013), and may represent a broader population of HCMV-adapted NK cells. Fc ϵ R γ -deficient NK cells have a mature phenotype, a variable but higher expression of NKG2C, and show robust antibody-mediated expansion and cytokine production driven by Fc γ RIIIa (CD16) (Lee et al. 2015; Schlums et al. 2015; Liu et al. 2016; Rolle and Brodin 2016). Epigenetic changes in these cells leading to alter intracellular signaling pro-

teins and transcription factors provide a molecular basis for altered function in HCMV-adapted NK cells (Lee et al. 2015; Schlums et al. 2015).

The Yokoyama laboratory first showed that cytokine stimulation alone can lead to long-term enhanced NK cell responses. Using an adoptive transfer system, splenic murine NK cells were stimulated with a combination of IL-12/15/18 and transferred into naïve hosts. NK cells with a prior history of cytokine activation had enhanced IFN- γ responses to activating receptors, cytokines, and tumor targets weeks to months later (Cooper et al. 2009; Keppel et al. 2013). The Cerwenka Laboratory has shown that murine NK cells preactivated with IL-12/15/18 had enhanced IFN- γ and perforin-dependent antitumor activity in vivo, and were dependent on CD4⁺ T cells, macrophages, and IL-2 for

M.A. Cooper et al.

proliferation and long-term function (Ni et al. 2012, 2016). A similar form of cytokine-induced memory was shown in humans, using an in vitro culture system. Human NK cells, preactivated with cytokines (IL-12/15/18) and maintained in vitro with low-dose IL-15, displayed enhanced IFN- γ and tumor necrosis factor (TNF) production in response to restimulation with cytokines and primary acute myeloid leukemia (AML) blasts, and had enhanced killing of K562 tumor targets in vitro (Romee et al. 2012, 2016). These findings led us to carry out a first-in-human clinical trial of adoptive immunotherapy with IL-12/15/18-activated haploidentical NK cells in patients with relapsed/refractory AML. Preliminary results from this clinical trial show that NK cells expand and are detectable in the blood and bone marrow of patients, have enhanced functional activity compared with the recipient's own NK cells, and five of nine patients had clinical responses with four having complete remissions (Romee et al. 2016).

Together, these studies show memory and memory-like properties of mouse and human NK cells induced by different mechanisms, including antigen-specific (haptens, MCMV, VLPs), viral-driven (HCMV), and antigen-independent (cytokine-induced) forms of memory.

CAN NK CELL MEMORY PLAY A ROLE IN VACCINATION?

Knowing that NK cells can alter their function based on prior activation, should NK cells be targeted for vaccination? Current vaccination strategies target the ability of T and B lymphocytes to form long-lasting specific memory, protecting the host years after a single vaccination series. The discovery of memory in NK cells raises the question of whether they should also be targeted for vaccination. There are a number of factors to consider with regard to harnessing NK cell memory for vaccination. What type of NK cell memory should be targeted for vaccination? What vaccination strategy would best target NK cells? What is the life span and durability of memory NK cells? What is the correct model organism for preclinical testing of vaccination strategies?

Although all of these questions have scientific merit, perhaps the most important question when considering investment of resources to targeting NK cell memory is whether, in immunocompetent individuals, there is any advantage to targeting NK cells versus adaptive lymphocytes?

The best evidence for NK cell memory responses during vaccination comes from studies of liver-resident memory cells. Paust et al. (2010) showed that vaccination of T- and B-cell *Rag*-deficient mice with ultraviolet (UV)-irradiated vesicular stomatitis virus (VSV) provided protection against subsequent local infection with VSV, which was otherwise fatal in half of unimmunized mice. Using adoptive transfer models, they also showed that purified liver NK cells from *Rag*-deficient mice immunized 3 months before with influenza VLPs conferred a survival advantage to influenza A infection in T/B/NK-deficient (*Rag2^{-/-}IL2rg^{-/-}*) hosts, although transferred NK cells did not provide a long-term survival benefit. Interestingly, they also showed liver-resident NK-cell-mediated CHS in response to HIV-I containing VLPs, a virus for which murine NK cells would not be expected to have evolved a recognition mechanism. A recent study from van den Boom et al. showed antitumor liver-resident memory NK cell responses (van den Boorn et al. 2016). Sensitization with monobenzene led to haptenization of melanocyte antigens, with development of liver-resident memory NK cells capable of monobenzene-specific CHS and cytotoxic activity against pigmented cells. T- and B-cell-deficient mice sensitized with monobenzene had enhanced antitumor response to in vivo challenge with a melanoma tumor, correlating with increased activated NK cells present in tumors. Liver-resident NK cells from monobenzene-sensitized mice had enhanced cytotoxicity in vitro against melanoma cells or a syngeneic melanoma cell line, presumably the result of a shared melanocyte antigen. NK cell protection in this model was antigen-specific, as there was no enhanced response to a different tumor (sarcoma challenge) (van den Boorn et al. 2016).

Thus, murine studies show that vaccination with VLPs, irradiated virus, and haptens confer

Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?

liver-resident NK-mediated immunity to those antigens. However, a number of questions still exist with regard to this system. First, the mechanism by which liver-resident NK cells recognize a wide array of antigens is unknown, and suggests that they may have the potential to somatically rearrange their activating receptors for specific recognition. Without a basis for antigen recognition, it is challenging to design antigens and develop rational vaccine strategies. Second, it is unknown whether human liver-resident NK cells (or other tissue-specific NK cell subsets) have a similar capacity to specifically recognize a wide array of antigens. Preliminary evidence in rhesus macaques suggests a similar type of NK cell memory in primates (Reeves et al. 2015). However, because these studies were performed in immunocompetent organisms that produce antibodies, it cannot be excluded that NK cell memory is mediated by specific antibodies that engage and activate Fc receptors on NK cells. Moreover, further investigation in humans is necessary.

There is no direct evidence for vaccination strategies with CMV- or cytokine-induced NK cell memory. NK cell memory observed after MCMV infection is specific to a model system in which half of the NK cells that express a germline-encoded receptor recognize a specific virally encoded antigen, and no such situation is known to exist in humans. One possibility this system does suggest with regard to vaccination is that NK cell stimulation via a specific activating receptor might lead to enhanced functional responses when that receptor is triggered in the future. Indeed, the Lanier Laboratory also showed that, in the context of an inflammatory challenge (low-dose m157-deficient MCMV infection), stimulation of murine NK cells via Ly49D, a cell-surface-activating receptor that recognizes an MHC class I molecule (H2-D^d), led to a similar form of NK cell memory as the Ly49H-m157 MCMV system (Nabekura and Lanier 2014). Ly49D-sensitized NK cells had enhanced degranulation and IFN- γ production in response to H2-D^d-positive tumors. These findings suggest the potential for a vaccination strategy targeting activating receptors on NK cells. For example, NKG2D is an activating receptor

present on the majority of mouse and human NK cells (and T cells). NKG2D recognizes several self-encoded stress ligands up-regulated on tumor and infected cells. If NKG2D-bearing NK cells were targeted with vaccination, it is possible that those cells would have enhanced tumor immunosurveillance and responses to “stressed” cells, including virally infected cells.

The viral trigger driving the differentiation of HCMV-adapted NK cells is unknown, thus presenting a challenge to vaccination strategies targeting these cells. The usage of inducing HCMV-adapted NK cells by vaccination is unclear, because most individuals acquire HCMV infection early during life, generating HCMV-adapted NK cells in situ. In addition, it is unknown whether the presence of HCMV-adapted NK cells benefits the host. Interestingly, there was a case report of an infant with a T-cell deficiency who contracted HCMV and showed massive expansion of NKG2C⁺ NK cells, with apparent control of infection before initiation of antivirals (Kuijpers et al. 2008). This suggests that HCMV-adapted NK cells may have an antiviral effect in patients. HCMV-adapted NK cells also expand during several other viral infections (in HCMV-seropositive individuals), and have enhanced antibody-dependent Fc γ RIIIa-mediated responses, suggesting that they have a functional role in human health (Rolle and Brodin 2016). Thus, vaccination strategies targeted at differentiating HCMV-adapted NK cells might be a rational strategy in individuals for whom a natural infection could be lethal, such as neonates and HCMV-negative pregnant women, immunocompromised individuals, and patients undergoing hematopoietic cell transplantation (HCT). Development of such a vaccine will require more knowledge of the factors driving differentiation and maintenance of HCMV-adapted NK cells.

Cytokine-induced memory-like NK cells arise after a brief exposure to IL-12, IL-18, and IL-15, with similar biology between murine models and humans. Several properties suggest that this type of preactivation that results in NK-cell memory-like differentiation may be harnessed using vaccine-type approaches. First, memory-like NK cells are long-lived, and pass

M.A. Cooper et al.

on their enhanced functionality to daughter cells after cell division, evidenced by detection 4 months after adoptive transfer in syngeneic mice (Cooper et al. 2009). Second, the stimulatory proinflammatory cytokines are well characterized, and conventional naïve NK cells constitutively express their receptors. Third, these cytokines are produced by dendritic cells and macrophages, and in theory cytokine-induced memory-like NK cells differentiate after an encounter with a matured, activated dendritic cell at the site of infection or other robust proinflammatory signal. Systemic administration of IL-12, IL-15, and IL-18 is not feasible, as these result in a toxic-shock response (Carson et al. 2000). However, local provision or induction may be a viable nontoxic strategy. For example, injection of Toll-like receptor agonists, which are being explored in clinical investigations in several types of immunotherapy (Shirota and Klinman 2014; Hammerich et al. 2016), induces a self-limited proinflammatory cytokine cascade that may result in NK cell memory-like responses. In theory, local injection of recombinant IL-12, IL-15, and IL-18 may also be feasible, for example, at the site of a tumor or within a single lymph node. With recent progress in protein engineering, it may be feasible to target a heterocytokine complex to a specific target cell or location. For example, using a single-chain variable fragment (scFv) fusion protein to target IL-12, IL-15, and IL-18 simultaneously to the site of a tumor. Although these strategies are supported by the activity of IL-12/15/18-induced memory-like NK cells, and are translatable, initial feasibility studies in mice, followed by careful in-human studies will be required to test their practicality and effectiveness. To this end, further study of memory-like NK cell biology, including the ability to identify and track these cells in vivo in mice and humans, will be a critical area of study.

ILCs: POTENTIAL FOR MEMORY FUNCTIONS AND IMPACT IN VACCINATION

Although NK cells can be considered the innate counterparts of CD8⁺ cytotoxic T cells, ILCs resemble CD4⁺ T-helper (T_H)-cell subsets (Diefenbach et al. 2014; Eberl et al. 2015). ILCs in-

clude three major classes—ILC1s, ILC2s, and ILC3s—which are defined based on the signature cytokines they produce: ILC1s secrete IFN- γ , ILC2s produce IL-5 and IL-13, and ILC3s secrete IL-22 and IL-17. Thus, ILCs can be considered the innate counterparts of T_H1, T_H2, and T_H17 cells, as they share functional modules that encompass cytokine secretion as well as transcription factors that underpin cytokine specialization (Diefenbach et al. 2014; Eberl et al. 2015).

ILCs lack the antigen-specific receptors of CD4⁺ T cells and do not express receptors analogous to the CMV receptors of NK cells; what triggers their activation? In fact, ILCs respond directly to cytokine signals in the microenvironment. Specificity is controlled by the cytokine receptors that ILCs express, which allows distinct combinations of myeloid and/or tissue-produced cytokines to activate each ILC class. IL-12, IL-18, and IL-15 trigger ILC1s; IL-25, thymic stromal lymphopoietin (TSLP), and IL-33 stimulate ILC2s; and IL-23 and IL-1 β prompt ILC3s (Diefenbach et al. 2014; Eberl et al. 2015).

To date, there is no evidence that ILCs are capable of memory responses. Given that cytokine receptors are the major trigger of ILC activation and cytokine production, it is likely that cytokine stimulation alone may lead to enhanced long-term ILC responses, as is observed for NK cells. Supporting this hypothesis, recent epigenetic studies have shown that the regulatory circuitries that control ILC effector functions contain active enhancers as well as poised enhancers, which can be further activated by cytokine stimulation (Koues et al. 2016; Shih et al. 2016). Thus, repeated cytokine stimulation is likely to enhance and sustain ILC responses over time, resulting in the generation of ILC memory-like cells.

Given that ILC1s have been identified in tumors (Dadi et al. 2016) and that intestinal ILC3s and ILC1s have been shown to augment host resistance to viral and bacterial infections (Abt et al. 2015; Hernandez et al. 2015), memory-like ILC1s and ILC3s could be harnessed for vaccine-type approaches. For example, administration of stimuli for ILC1s, such as IL-12 and IL-15, at the site of a tumor may enhance tumor

Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?

immunosurveillance. Similarly, introducing IL-23 or other stimuli for ILC3s into the intestinal tract may reinforce pathogen immunosurveillance. A subset of ILC3s corresponds to lymphoid tissue inducer cells, which are endowed with the capacity to induce lymphoid organs (Bar-Ephraim and Mebius 2016) and produce B-cell stimulatory factors in humans (Cella et al. 2010); given this, ILC3s might also be exploited to boost adaptive responses, particularly antibody responses (Reboldi et al. 2016).

However, recent studies on the function of ILCs in the context of immunocompetent mice have shown a considerable redundancy between ILCs and CD4⁺ T_H-cell subsets (Song et al. 2015; Rankin et al. 2016). Thus, it remains to be tested what role, if any, ILC memory cells may have in the protection from pathogens or tumors in immunocompetent organisms.

THE THREE MOST IMPORTANT QUESTIONS FOR THE FIELD TO MOVE FORWARD WITH NK-CELL- AND ILC-BASED VACCINATION STRATEGIES

Although research during the past decade has led to the discovery of NK cell memory and ILC subsets, three questions remain open: What is the longevity of memory NK cells and ILCs? How do studies in model organisms translate to humans? Would targeting NK cells and ILCs provide any advantage to immunocompetent patients? Addressing these fundamental questions will be essential to decide whether NK cells and ILCs can be harnessed for vaccination strategies.

ACKNOWLEDGMENTS

We thank Susan Gilfillan for critical comments.

REFERENCES

- Abt MC, Lewis BB, Caballero S, Xiong H, Carter RA, Susac B, Ling L, Leiner I, Pamer EG. 2015. Innate immune defenses mediated by two ILC subsets are critical for protection against acute *Clostridium difficile* infection. *Cell Host Microbe* **18**: 27–37.
- Bar-Ephraim YE, Mebius RE. 2016. Innate lymphoid cells in secondary lymphoid organs. *Immunol Rev* **271**: 185–199.
- Carson WE, Dierksheide JE, Jabbour S, Anghelina M, Bouchard P, Ku G, Yu H, Baumann H, Shah MH, Cooper MA, et al. 2000. Coadministration of interleukin-18 and interleukin-12 induces a fatal inflammatory response in mice: Critical role of natural killer cell interferon- γ production and STAT-mediated signal transduction. *Blood* **96**: 1465–1473.
- Cella M, Otero K, Colonna M. 2010. Expansion of human NK-22 cells with IL-7, IL-2, and IL-1 β reveals intrinsic functional plasticity. *Proc Natl Acad Sci* **107**: 10961–10966.
- Cooper MA, Elliott JM, Keyel PA, Yang L, Carrero JA, Yokoyama WM. 2009. Cytokine-induced memory-like natural killer cells. *Proc Natl Acad Sci* **106**: 1915–1919.
- Dadi S, Chhangawala S, Whitlock BM, Franklin RA, Luo CT, Oh SA, Toure A, Pritykin Y, Huse M, Leslie CS, et al. 2016. Cancer immunosurveillance by tissue-resident innate lymphoid cells and innate-like T cells. *Cell* **164**: 365–377.
- Diefenbach A, Colonna M, Koyasu S. 2014. Development, differentiation, and diversity of innate lymphoid cells. *Immunity* **41**: 354–365.
- Dokun AO, Kim S, Smith HR, Kang HS, Chu DT, Yokoyama WM. 2001. Specific and nonspecific NK cell activation during virus infection. *Nat Immunol* **2**: 951–956.
- Eberl G, Colonna M, Di Santo JP, McKenzie AN. 2015. Innate lymphoid cells: A new paradigm in immunology. *Science* **348**: aaa6566.
- Foley B, Cooley S, Verneris MR, Pitt M, Curtsinger J, Luo X, Lopez-Verges S, Lanier LL, Weisdorf D, Miller JS. 2012. Cytomegalovirus reactivation after allogeneic transplantation promotes a lasting increase in educated NKG2C⁺ natural killer cells with potent function. *Blood* **119**: 2665–2674.
- Guma M, Angulo A, Vilches C, Gomez-Lozano N, Malats N, Lopez-Botet M. 2004. Imprint of human cytomegalovirus infection on the NK cell receptor repertoire. *Blood* **104**: 3664–3671.
- Hammerich L, Bhardwaj N, Kohrt HE, Brody JD. 2016. In situ vaccination for the treatment of cancer. *Immunotherapy* **8**: 315–330.
- Hernandez PP, Mahlakoiv T, Yang I, Schwierzeck V, Nguyen N, Guendel F, Gronke K, Ryffel B, Holscher C, Dumoutier L, et al. 2015. Interferon- λ and interleukin 22 act synergistically for the induction of interferon-stimulated genes and control of rotavirus infection. *Nat Immunol* **16**: 698–707.
- Holmes TD, Bryceson YT. 2016. Natural killer cell memory in context. *Semin Immunol* **28**: 368–376.
- Hwang I, Zhang T, Scott JM, Kim AR, Lee T, Kakarla T, Kim A, Sunwoo JB, Kim S. 2012. Identification of human NK cells that are deficient for signaling adaptor FcR γ and specialized for antibody-dependent immune functions. *Int Immunol* **24**: 793–802.
- Keppel MP, Yang L, Cooper MA. 2013. Murine NK cell intrinsic cytokine-induced memory-like responses are maintained following homeostatic proliferation. *J Immunol* **190**: 4754–4762.
- Koues OI, Collins PL, Cella M, Robinette ML, Porter SI, Pyfrom SC, Payton JE, Colonna M, Oltz EM. 2016. Distinct gene regulatory pathways for human innate versus adaptive lymphoid cells. *Cell* **165**: 1134–1146.

M.A. Cooper et al.

- Kuijpers TW, Baars PA, Dantin C, van den Burg M, van Lier RA, Roosnek E. 2008. Human NK cells can control CMV infection in the absence of T cells. *Blood* **112**: 914–915.
- Lee J, Zhang T, Hwang I, Kim A, Nitschke L, Kim M, Scott JM, Kamimura Y, Lanier LL, Kim S. 2015. Epigenetic modification and antibody-dependent expansion of memory-like NK cells in human cytomegalovirus-infected individuals. *Immunity* **42**: 431–442.
- Liu LL, Landskron J, Ask EH, Enqvist M, Sohlberg E, Traherne JA, Hammer Q, Goodridge JP, Larsson S, Jayaraman J, et al. 2016. Critical role of CD2 co-stimulation in adaptive natural killer cell responses revealed in NKG2C-deficient humans. *Cell Rep* **15**: 1088–1099.
- Majewska-Szczepanik M, Paust S, von Andrian UH, Askenase PW, Szczepanik M. 2013. Natural killer cell-mediated contact sensitivity develops rapidly and depends on interferon- α , interferon- γ and interleukin-12. *Immunology* **140**: 98–110.
- Min-Oo G, Lanier LL. 2014. Cytomegalovirus generates long-lived antigen-specific NK cells with diminished bystander activation to heterologous infection. *J Exp Med* **211**: 2669–2680.
- Nabekura T, Lanier LL. 2014. Antigen-specific expansion and differentiation of natural killer cells by alloantigen stimulation. *J Exp Med* **211**: 2455–2465.
- Ni J, Miller M, Stojanovic A, Garbi N, Cerwenka A. 2012. Sustained effector function of IL-12/15/18-preactivated NK cells against established tumors. *J Exp Med* **209**: 2351–2365.
- Ni J, Holsken O, Miller M, Hammer Q, Luetke-Eversloh M, Romagnani C, Cerwenka A. 2016. Adoptively transferred natural killer cells maintain long-term anti-tumor activity by epigenetic imprinting and CD4⁺ T cell help. *Oncoimmunology* **5**: e1210009.
- O'Leary JG, Goodarzi M, Drayton DL, von Andrian UH. 2006. T cell- and B cell-independent adaptive immunity mediated by natural killer cells. *Nat Immunol* **7**: 507–516.
- O'Sullivan TE, Sun JC, Lanier LL. 2015. Natural killer cell memory. *Immunity* **43**: 634–645.
- Paust S, Gill HS, Wang BZ, Flynn MP, Moseman EA, Senman B, Szczepanik M, Telenti A, Askenase PW, Compans RW, et al. 2010. Critical role for the chemokine receptor CXCR6 in NK cell-mediated antigen-specific memory of haptens and viruses. *Nat Immunol* **11**: 1127–1135.
- Peng H, Jiang X, Chen Y, Sojka DK, Wei H, Gao X, Sun R, Yokoyama WM, Tian Z. 2013. Liver-resident NK cells confer adaptive immunity in skin-contact inflammation. *J Clin Invest* **123**: 1444–1456.
- Rankin LC, Girard-Madoux MJ, Seillet C, Mielke LA, Kerdiles Y, Fenis A, Wieduwild E, Putoczki T, Mondot S, Lantz O, et al. 2016. Complementarity and redundancy of IL-22-producing innate lymphoid cells. *Nat Immunol* **17**: 179–186.
- Reboldi A, Arnon TI, Rodda LB, Atakilit A, Sheppard D, Cyster JG. 2016. IgA production requires B cell interaction with subepithelial dendritic cells in Peyer's patches. *Science* **352**: aaf4822.
- Reeves RK, Li H, Jost S, Blass E, Li H, Schafer JL, Varner V, Manickam C, Eslamizar L, Altfeld M, et al. 2015. Antigen-specific NK cell memory in rhesus macaques. *Nat Immunol* **16**: 927–932.
- Rolle A, Brodin P. 2016. Immune adaptation to environmental influence: The case of NK cells and HCMV. *Trends Immunol* **37**: 233–243.
- Romee R, Schneider SE, Leong JW, Chase JM, Keppel CR, Sullivan RP, Cooper MA, Fehniger TA. 2012. Cytokine activation induces human memory-like NK cells. *Blood* **120**: 4751–4760.
- Romee R, Rosario M, Berrien-Elliott MM, Wagner JA, Jewell BA, Schappe T, Leong JW, Abdel-Latif S, Schneider SE, Willey S, et al. 2016. Cytokine-induced memory-like natural killer cells exhibit enhanced responses against myeloid leukemia. *Sci Transl Med* **8**: 357ra123.
- Schlums H, Cichocki F, Tesi B, Theorell J, Beziat V, Holmes TD, Han H, Chiang SC, Foley B, Mattsson K, et al. 2015. Cytomegalovirus infection drives adaptive epigenetic diversification of NK cells with altered signaling and effector function. *Immunity* **42**: 443–456.
- Shih HY, Sciume G, Mikami Y, Guo L, Sun HW, Brooks SR, Urban JF Jr, Davis FP, Kanno Y, O'Shea JJ. 2016. Developmental acquisition of regulomes underlies innate lymphoid cell functionality. *Cell* **165**: 1120–1133.
- Shirota H, Klinman DM. 2014. Recent progress concerning CpG DNA and its use as a vaccine adjuvant. *Expert Rev Vaccines* **13**: 299–312.
- Song C, Lee JS, Gilfillan S, Robinette ML, Newberry RD, Stappenbeck TS, Mack M, Cella M, Colonna M. 2015. Unique and redundant functions of NKp46⁺ ILC3s in models of intestinal inflammation. *J Exp Med* **212**: 1869–1882.
- Sun JC, Beilke JN, Lanier LL. 2009. Adaptive immune features of natural killer cells. *Nature* **457**: 557–561.
- van den Boorn JG, Jakobs C, Hagen C, Renn M, Luiten RM, Melief CJ, Tuting T, Garbi N, Hartmann G, Hornung V. 2016. Inflammasome-dependent induction of adaptive NK cell memory. *Immunity* **44**: 1406–1421.
- Wagner JA, Fehniger TA. 2016. Human adaptive natural killer cells: Beyond NKG2C. *Trends Immunol* **37**: 351–353.
- Yokoyama WM. 2013. Natural killer cells. In *Fundamental immunology* (ed. Paul W), pp. 395–430. Lippincott, Williams & Wilkins, Philadelphia.
- Zhang T, Scott JM, Hwang I, Kim S. 2013. Cutting edge: Antibody-dependent memory-like NK cells distinguished by Fc γ deficiency. *J Immunol* **190**: 1402–1406.

Cold Spring Harbor Perspectives in Biology

Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?: Vaccination Strategies Based on NK Cell and ILC Memory

Megan A. Cooper, Todd A. Fehniger and Marco Colonna

Cold Spring Harb Perspect Biol 2018; doi: 10.1101/cshperspect.a029512 originally published online December 18, 2017

Subject Collection [Immune Memory and Vaccines: Great Debates](#)

Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?: Can Natural Killer and CD8 T Cells Switch Jobs?

Christine A. Biron and Marcus Altfeld

Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?: Vaccination Strategies Based on NK Cell and ILC Memory

Megan A. Cooper, Todd A. Fehniger and Marco Colonna

Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?: Neoantigens as Vaccine Targets for Cancer

Haydn T. Kissick

Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?: Neoantigens: Nothing New in Spite of the Name

Olivera J. Finn and Hans-Georg Rammensee

Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?: NK Cell Memory and Immunization Strategies against Infectious Diseases and Cancer

Joseph C. Sun and Lewis L. Lanier

Is There Natural Killer Cell Memory and Can It Be Harnessed by Vaccination?: Natural Killer Cells in Vaccination

Harold R. Neely, Irina B. Mazo, Carmen Gerlach, et al.

Is It Possible to Develop Cancer Vaccines to Neoantigens, What Are the Major Challenges, and How Can These Be Overcome?: Targeting the Right Antigens in the Right Patients

Stephen P. Schoenberger

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?: There Is Only One True Winner

Scott B. Halstead

For additional articles in this collection, see <http://cshperspectives.cshlp.org/cgi/collection/>

**All Modifications and
Oligo Types Synthesized**

Long Oligos • Fluorescent • Chimeric • DNA • RNA • Antisense

Oligo Modifications?

Your wish is our command.

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?: The Challenges of a Dengue Vaccine

Gavin Screaton and Juthathip Mongkolsapaya

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?: The Path to a Dengue Vaccine: Learning from Human Natural Dengue Infection Studies and Vaccine Trials

Aravinda M. de Silva and Eva Harris

Is It Possible to Develop a "Universal" Influenza Virus Vaccine?: Potential for a Universal Influenza Vaccine

James E. Crowe, Jr.

Is It Possible to Develop a "Universal" Influenza Virus Vaccine?: Outflanking Antibody Immunodominance on the Road to Universal Influenza Vaccination

Davide Angeletti and Jonathan W. Yewdell

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?: Questions Raised by the Development and Implementation of Dengue Vaccines: Example of the Sanofi Pasteur Tetravalent Dengue Vaccine

Bruno Guy

Which Dengue Vaccine Approach Is the Most Promising, and Should We Be Concerned about Enhanced Disease after Vaccination?: The Risks of Incomplete Immunity to Dengue Virus Revealed by Vaccination

Stephen S. Whitehead and Kanta Subbarao

Is It Possible to Develop a "Universal" Influenza Virus Vaccine?: Immunogenetic Considerations Underlying B-Cell Biology in the Development of a Pan-Subtype Influenza A Vaccine Targeting the Hemagglutinin Stem

Sarah F. Andrews, Barney S. Graham, John R. Mascola, et al.

Is It Possible to Develop a "Universal" Influenza Virus Vaccine?: Potential Target Antigens and Critical Aspects for a Universal Influenza Vaccine

Florian Krammer, Adolfo García-Sastre and Peter Palese

For additional articles in this collection, see <http://cshperspectives.cshlp.org/cgi/collection/>

All Modifications and Oligo Types Synthesized

Oligo Modifications?
Your wish is our command.

Long Oligos • Fluorescent • Chimeric • DNA • RNA • Antisense